J&J and Legend’s CAR-T Therapy Better Than Standard Care in Phase III Trial
January 27, 2023
J&J and Legend Biotech have announced new results from their CARTITUDE-4 trial that shows their new CAR-T therapy Carvykti is more effective at treating multiple myeloma than standard care. The companies say that the therapy, which many predict to be an upcoming blockbuster, has achieved the trials primary endpoint of progression-free survival.
According to Max Gelman, “Carvykti is expected to be one of J&J’s top upcoming moneymakers, and the Big Pharma has carefully laid out plans to make it a bestseller. The first was getting it approved last February for relapsed or refractory MM patients who have received at least four previous therapies.”
To read more, click here.
(Source: Endpoints News, January 27th, 2023)
